Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Olistico Wealth LLC

Olistico Wealth LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 30.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 785 shares of the medical research company’s stock after acquiring an additional 185 shares during the period. Olistico Wealth LLC’s holdings in Amgen were worth $245,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Novare Capital Management LLC acquired a new position in Amgen in the first quarter valued at approximately $211,000. Adell Harriman & Carpenter Inc. raised its position in Amgen by 17.7% in the first quarter. Adell Harriman & Carpenter Inc. now owns 19,178 shares of the medical research company’s stock valued at $5,975,000 after purchasing an additional 2,890 shares during the period. Concurrent Investment Advisors LLC raised its position in Amgen by 10.1% in the first quarter. Concurrent Investment Advisors LLC now owns 21,480 shares of the medical research company’s stock valued at $6,692,000 after purchasing an additional 1,978 shares during the period. HM Payson & Co. lifted its stake in shares of Amgen by 5.6% in the 1st quarter. HM Payson & Co. now owns 218,010 shares of the medical research company’s stock valued at $67,921,000 after purchasing an additional 11,611 shares during the last quarter. Finally, World Investment Advisors grew its holdings in shares of Amgen by 1.2% during the 1st quarter. World Investment Advisors now owns 16,959 shares of the medical research company’s stock worth $5,284,000 after purchasing an additional 193 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.5%

AMGN opened at $298.25 on Friday. The business has a fifty day moving average price of $282.47 and a 200 day moving average price of $286.99. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a market capitalization of $160.37 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 2.70 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.05 billion. During the same quarter last year, the business posted $3.96 EPS. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. Royal Bank Of Canada dropped their price target on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. UBS Group reissued a “neutral” rating and issued a $315.00 price target (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Mizuho increased their price objective on shares of Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 7th. Finally, Guggenheim started coverage on Amgen in a research report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $307.82.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.76% of the stock is owned by company insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.